title: Involvement of somatodendritic 5-HT(1A) receptors in Delta(9)-tetrahydrocannabinol-induced hypothermia in the rat.
abstract: Previously, it has been reported that modulating serotonergic neurones by use of selective serotonin reuptake inhibitors (SSRI) can alter the hypothermic response produced by Delta(9)-tetrahydrocannabinol (Delta(9)-THC). The aim of the present study was to investigate the effect that activation or antagonism of 5-hydroxytryptamine (5-HT(1A)) receptors has on Delta(9)-THC-induced hypothermia. Delta(9)-THC (0.5, 2 and 5 mg/kg iv) decreased body temperature in a dose-related manner. Whilst having no significant effect on body temperature when administered 40 min prior to vehicle injection, the 5-HT(1A) receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride (WAY 100635; 1 mg/kg sc) significantly potentiated the hypothermia produced by 2 and 5 mg/kg Delta(9)-THC. In order to investigate whether this effect was due to antagonism at somatodendritic autoreceptors in midbrain raphe nuclei, WAY 100635 or the 5-HT(1A) agonist 8-hydroxy-(di-n-propylamino) tetralin (8-OH-DPAT) was microinjected into either the median raphe nuclei (MRN) or dorsal raphe nuclei (DRN) 40 min prior to Delta(9)-THC injection. Following microinjection into the DRN, neither WAY 100635 (0.5 nmol/0.5 microl/10 s) nor 8-OH-DPAT (15.2 nmol/0.5 microl/10 s) had any significant effect on Delta(9)-THC-induced hypothermia. However, WAY 100635 when microinjected into the MRN significantly potentiated Delta(9)-THC-induced hypothermia, and 8-OH-DPAT microinjected into the MRN significantly inhibited Delta(9)-THC-induced hypothermia. It is suggested from these studies that the potentiation of Delta(9)-THC-induced hypothermia by WAY 100635 when administered peripherally is mainly due to antagonism at somatodendritic 5-HT(1A) autoreceptors in the MRN.
authors.affiliation: Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville 3052, Victoria, Australia. dan.malone@vcp.monash.edu.au
authors.forename: D T
authors.initials: DT
authors.lastname: Malone
authors.forename: D A
authors.initials: DA
authors.lastname: Taylor
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology; D000818:Animals; D001831:Body Temperature / Q000187:drug effects* / Q000502:physiology; D013759:Dronabinol / Q000494:pharmacology*; D005260:Female; D006213:Hallucinogens / Q000494:pharmacology*; D007035:Hypothermia / Q000139:chemically induced*; D010879:Piperazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011903:Raphe Nuclei / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D011985:Receptors, Serotonin / Q000502:physiology*; D044263:Receptors, Serotonin, 5-HT1; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology
chemical_list: D006213:Hallucinogens; D010879:Piperazines; D011725:Pyridines; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D013759:Dronabinol